Welcome to our dedicated page for Evaxion Biotech A/S American Depositary Share news (Ticker: $EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion Biotech A/S American Depositary Share stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Evaxion Biotech A/S American Depositary Share's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Evaxion Biotech A/S American Depositary Share's position in the market.
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) announces significant progress in its Phase 2 clinical trial for the personalized cancer vaccine EVX-01, with the first patient completing dosing. The trial, focusing on metastatic melanoma patients, aims to assess efficacy, safety, and immune response induction. Each patient receives a unique vaccine tailored to their biology, with ten doses administered over 78 weeks in combination with KEYTRUDA®. The one-year clinical efficacy readout is expected in Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.73%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) and its collaborator have successfully tested Evaxion-designed vaccine antigens against Staphylococcus aureus in large non-rodent animals, showing promising results for clinical efficacy in human trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.12%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S announces Precision Vaccine Project targeting cancer vaccine development with AI-identified targets. MSD collaboration progresses with funding from private and public offerings. MSD GHI becomes the largest shareholder. Business update includes successful financing rounds and R&D Day showcasing AI-Immunology™ platform.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.15%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) hosts a Research & Development Day showcasing its AI-Immunology™ platform, revolutionizing vaccine discovery using advanced AI and machine learning technologies. The platform offers scalability, adaptability, and partnerships with established players like MSD. The event highlights the innovative AI building blocks PIONEER™, ObsERV™, EDEN™, and RAVEN™ for rapid vaccine target identification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) will host a Research & Development Day on March 19, 2024, showcasing its AI-Immunology™ platform for vaccine development. The event will feature talks from scientists, highlighting the platform's predictive capabilities for addressing medical needs in cancer and infectious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) successfully completes initial phases of vaccine collaboration with MSD, a leading pharma company, showcasing the potential of AI-Immunology™ powered vaccines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced that it has regained compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2). The closing bid price of the Company’s American Depositary Shares has been at $1.00 per share or greater for ten consecutive business days from January 22, 2024, to February 02, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (EVAX) closed a public offering of 3,750,000 of its American Depositary Shares (ADSs) and warrants, raising $15 million. MSD Global Health Innovation Fund, a shareholder since December 2023, participated in the offering. The net proceeds will be used to advance the preclinical and clinical pipeline and for operating expenses and working capital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.88%
Tags
-
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) has announced the pricing of a public offering of 3,750,000 of its American Depositary Shares (ADSs) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS. MSD Global Health Innovation Fund, a shareholder since December 2023, is also participating in this offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.05%
Tags
Rhea-AI Summary
Evaxion Biotech A/S (NASDAQ: EVAX) is expanding its commitment to developing tailored cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs). This AI-Immunology™ powered vaccine concept offers the potential to provide treatment solutions to cancer patients unresponsive to conventional cancer immunotherapy. The company aims to generate Proof-of-Concept data by the second half of 2024, with a focus on delivering treatment solutions to previously unresponsive cancer patients. Evaxion's Chief Scientific Officer, Birgitte Rønø, expresses optimism about the significant potential of ERV-based vaccines and the company's commitment to improving healthcare through innovative and AI-powered approaches. The company also presented recent insights at the American Society of Hematology (ASH) Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
113.43%
Tags
Evaxion Biotech A/S American Depositary Share
Nasdaq:EVAX
EVAX Rankings
EVAX Stock Data
21.16M
36.13M
16.6%
0.93%
0.82%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
Horsholm
About EVAX
since 2008, evaxion biotech has been pioneering discovery of antigens and neo-epitopes for vaccines and antibodies using artificial intelligence, with the mission to solve some of the world’s most significant challenges to human health. evaxion has constructed a robust product engine for the development of novel vaccines and therapies based on our two platforms, pioneer and eden. using state of the art in silico tools, the platforms integrate big data, artificial intelligence and supercomputing to predict, rank and optimize epitopes and antigens that elicit a highly protective immune response against cancers and infectious diseases. eden enables rapid and accurate discovery of novel antigens that elicit a highly cross-protective immune response in any bacterial pathogen while pioneer has been constructed to identify the epitopes of mutated proteins that will fire up the body’s natural immune responses to them. to learn more about evaxion, please visit http://www.evaxion-biotech.ai